ANEB

Anebulo Pharmaceuticals, Inc. is a clinical-stage biotechnology company. It is engaged in developing treatments for cannabis toxicity, such as unintentional cannabis poisoning, acute cannabinoid intoxication (ACI) and the landscape of acute cannabis-induced conditions. Its lead product candidate is selonabant, a potent, small molecule antagonist of cannabinoid binding receptor type-1 (CB1), the primary receptor involved in the psychotropic effects of cannabinoids, with the potential to address the unmet medical need for a therapy to treat cannabis toxicity. Selonabant is orally bioavailable, rapidly absorbed, and has also been formulated for intravenous administration. Selonabant is intended to rapidly reverse the negative effects of cannabis-induced toxicity and reduce time to recovery. It is also prioritizing the advancement of a selonabant intravenous (IV) formulation as a potential treatment for pediatric patients with cannabis-induced CNS depression.

Wall Street analysts forecast ANEB stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for ANEB is  USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Anebulo Pharmaceuticals Inc revenue for the last quarter amounts to -2.26M USD, decreased -6.30 % YoY.

Anebulo Pharmaceuticals Inc. EPS for the last quarter amounts to USD, decreased % YoY.

Anebulo Pharmaceuticals Inc (ANEB) has 2 emplpoyees as of December 15 2025.

Today ANEB has the market capitalization of 94.08M USD.